Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.57 |
| ▸ | SQLE | Q14534 | 7/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | FNTA | P49354 | 1/20 | 0.47 |
| ▸ | FNTB | P49356 | 1/20 | 0.47 |
| ▸ | ICMT | O60725 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3050478 | 1.00 | KMT2A (0.64) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL3090453 | 1.00 | KMT2A (0.64) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL3050479 | 1.00 | KMT2A (0.64) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL7279044 | 0.87 | — | — | |
| SCHEMBL3100180 | 0.86 | KMT2A (0.45) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL3100176 | 0.86 | KMT2A (0.45) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL28653661 | 0.81 | KMT2A (0.67) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL23802597 | 0.79 | KMT2A (1.00) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL8013144 | 0.79 | KMT2A (1.00) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| Squalene SCHEMBL890053 | 0.79 | KMT2A (1.00) | KMT2AMAPTMEN1CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353805-A1 | PROCESS | GIVAUDAN SA (CH) | 2025-11-20 | — | — | US | claimed |
| US-20250353805-A1 | PROCESS | GIVAUDAN SA (CH) | 2025-11-20 | — | — | US | disclosed |
| US-20250353805-A1 | PROCESS | GIVAUDAN SA (CH) | 2025-11-20 | — | — | US | disclosed |
| EP-4452914-A1 | PROCESS | Givaudan SA (CH) | 2024-10-30 | — | — | EP | disclosed |
| EP-4452914-A1 | PROCESS | Givaudan SA (CH) | 2024-10-30 | — | — | EP | disclosed |
| US-11965195-B2 | Enzyme mediated process | GIVAUDAN SA (CH) | 2024-04-23 | — | — | US | disclosed |
| WO-2023118051-A1 | PROCESS | GIVAUDAN SA (CH) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023118051-A1 | PROCESS | GIVAUDAN SA (CH) | 2023-06-29 | — | — | WO | disclosed |
| US-20230009254-A1 | ENZYME MEDIATED PROCESS | GIVAUDAN SA (CH) | 2023-01-12 | — | — | US | disclosed |
| EP-4069858-A1 | ENZYME MEDIATED PROCESS | Givaudan SA (CH) | 2022-10-12 | — | — | EP | disclosed |
| WO-2021110858-A1 | ENZYME MEDIATED PROCESS | GIVAUDAN SA (CH) | 2021-06-10 | — | — | WO | disclosed |
| US-8629268-B2 | Cyclisation process of forming a multiple ring compound | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2014-01-14 | — | — | US | disclosed |
| US-20130046090-A1 | CYCLISATION PROCESS OF FORMING A MULTIPLE RING COMPOUND | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2013-02-21 | — | — | US | disclosed |
| US-8227645-B2 | Cyclisation process of forming a multiple ring compound | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2012-07-24 | — | — | US | disclosed |
| US-20100228058-A1 | CYCLISATION PROCESS OF FORMING A MULTIPLE RING COMPOUND | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2010-09-09 | — | — | US | disclosed |
| WO-2007097719-A1 | CYCLISATION PROCESS OF FORMING A MULTIPLE RING COMPOUND | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2007-08-30 | — | — | WO | disclosed |
| US-5273969-A | A phosphonylmethylphosphoalkylaminoalkane derivative | E. R. SQUIBB & SONS, INC. (US) | 1993-12-28 | — | — | US | disclosed |
| US-5212164-A | Hypocholesterolemic and antiatherosclerotic agents | E. R. SQUIBB & SONS, INC. (US) | 1993-05-18 | — | — | US | disclosed |
| EP-0409181-A2 | Phosphorus-containing squalene synthetase inhibitors and method for their preparation | E.R. SQUIBB & SONS, INC. (US) | 1991-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100228058-A1 | CYCLISATION PROCESS OF FORMING A MULTIPLE RING COMPOUND | DHPS, GGPS1, COASY | KMT2A 2281/4885MAPT 4010/4885MEN1 458/4885 |
| US-20130046090-A1 | CYCLISATION PROCESS OF FORMING A MULTIPLE RING COMPOUND | COASY, AKR1C4, AKR1C2 | KMT2A 1729/4885MAPT 3702/4885MEN1 541/4885 |
| US-11965195-B2 | Enzyme mediated process | HPD, DNPH1, ESD | KMT2A 1439/4885MAPT 3201/4885MEN1 2090/4885 |
| US-20230009254-A1 | ENZYME MEDIATED PROCESS | HPD, DNPH1, ESD | KMT2A 1439/4885MAPT 3201/4885MEN1 2090/4885 |
| US-20250353805-A1 | PROCESS | DEGS1, FDFT1, SQLE | KMT2A 3167/4885MAPT 3835/4885MEN1 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.